PE20191404A1 - Proteinas de union al receptor de glucagon y metodos para usarlas - Google Patents
Proteinas de union al receptor de glucagon y metodos para usarlasInfo
- Publication number
- PE20191404A1 PE20191404A1 PE2019001477A PE2019001477A PE20191404A1 PE 20191404 A1 PE20191404 A1 PE 20191404A1 PE 2019001477 A PE2019001477 A PE 2019001477A PE 2019001477 A PE2019001477 A PE 2019001477A PE 20191404 A1 PE20191404 A1 PE 20191404A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- antibody
- glucagon receptor
- heavy chain
- light chain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Referido a un anticuerpo que se une especificamente al receptor de glucagon (GCGR) humano que comprende: (a) una CDR1 de cadena pesada que comprende GFTFTNHWLG (SEQ ID NO:1), una CDR2 de cadena pesada que comprende DIYPGGYYINYNEKFKG (SEQ ID NO:2) y una CDR3 de cadena pesada que comprende HTNYGSDY (SEQ ID NO:3); y (b) una CDR1 de cadena ligera que comprende RSSQSIVDSYGNTFLE (SEQ ID NO:4), una CDR2 de cadena ligera que comprende KVSNRLS (SEQ IN NO:5) y una CDR3 de cadena ligera que comprende FQGSHVPWT (SEQ ID NO:6). Este anticuerpo inhibe la senalizacion de GCGR en celulas que la expresan; tambien se refiere a un marcador como el radioisotopo, un quelante de metal, entre otros; el cual esta ligado al antigeno. Tambien se refiere a una celula que comprende o produce el anticuerpo, una composicion que comprende el anticuerpo, composicion farmaceutica, molecula de polinucleotido, un vector y su uso en el tratamiento de la diabetes tipo 1.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762451603P | 2017-01-27 | 2017-01-27 | |
| PCT/US2018/015452 WO2018140729A1 (en) | 2017-01-27 | 2018-01-26 | Glucagon receptor binding proteins and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20191404A1 true PE20191404A1 (es) | 2019-10-04 |
Family
ID=62979257
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2019001477A PE20191404A1 (es) | 2017-01-27 | 2018-01-26 | Proteinas de union al receptor de glucagon y metodos para usarlas |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US10995145B2 (es) |
| EP (1) | EP3573651A4 (es) |
| JP (1) | JP7005638B2 (es) |
| KR (1) | KR102627311B1 (es) |
| CN (1) | CN110520151B (es) |
| AU (1) | AU2018213374A1 (es) |
| BR (1) | BR112019015479A2 (es) |
| CA (1) | CA3048913A1 (es) |
| CL (1) | CL2019002081A1 (es) |
| CO (1) | CO2019009035A2 (es) |
| IL (1) | IL267638A (es) |
| MX (1) | MX2019008722A (es) |
| PE (1) | PE20191404A1 (es) |
| PH (1) | PH12019501605A1 (es) |
| SG (1) | SG11201906682YA (es) |
| WO (1) | WO2018140729A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2019008722A (es) | 2017-01-27 | 2019-10-02 | Ngm Biopharmaceuticals Inc | Proteínas de unión al receptor de glucagón y métodos para usarlas. |
| US10961315B2 (en) | 2018-07-27 | 2021-03-30 | Ngm Biopharmaceuticals, Inc. | Method of treating type I diabetes by administering a combination of a glucagon receptor antagonist and an anti-CD3 antibody |
| CN112996811B (zh) * | 2018-12-21 | 2022-11-22 | 江苏恒瑞医药股份有限公司 | 双特异性蛋白 |
| JP2023514010A (ja) * | 2020-01-10 | 2023-04-05 | ブライト ピーク セラピューティクス エージー | 修飾ｉｌ－２ポリペプチドおよびその使用 |
| WO2022083720A1 (zh) * | 2020-10-23 | 2022-04-28 | 江苏恒瑞医药股份有限公司 | Glp1-gcgr抗体融合蛋白变体及包含其的组合物 |
| KR20230004135A (ko) * | 2021-06-30 | 2023-01-06 | 한미약품 주식회사 | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체를 포함하는 조합물의 치료학적 용도 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK580789D0 (da) | 1989-11-20 | 1989-11-20 | Novo Nordisk As | Fremgangsmaade til oprensning af polypeptider |
| CA2142819C (en) | 1992-08-28 | 2003-08-19 | Wayne R. Kindsvogel | Glucagon receptors |
| US5776725A (en) | 1992-08-28 | 1998-07-07 | Zymogenetics, Inc. | Recombinant production of glucagon receptors |
| US20040037826A1 (en) | 2002-06-14 | 2004-02-26 | Michelsen Birgitte Koch | Combined use of a modulator of CD3 and a GLP-1 compound |
| WO2006005469A2 (en) | 2004-07-15 | 2006-01-19 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with glucagon receptor (gcgr) |
| CL2007002668A1 (es) | 2006-09-20 | 2008-05-09 | Amgen Inc | Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2. |
| EP2206775B1 (en) | 2007-09-26 | 2016-06-29 | Chugai Seiyaku Kabushiki Kaisha | Anti-il-6 receptor antibody |
| CA2703667C (en) | 2007-10-25 | 2015-12-29 | Lawrence M. Kauvar | Anti-rsv g protein antibodies |
| CL2009000586A1 (es) * | 2008-03-27 | 2010-06-04 | Lilly Co Eli | Fragmento fab o anticuerpo monoclonal humanizado que lo comprende que se une a receptor de glucagon humano/glucr, de rata, de raton, y mono cinomolgus; vector que comprende polinuccleotido codificante; celula huesped que lo comprende; composicion farmaceutica; uso para tratar diabetes tipo 1 o 2, o para la perdida de peso |
| EP2363471B1 (en) | 2008-10-31 | 2016-10-12 | Toray Industries, Inc. | Immunoassay method for human cxcl1 protein |
| CN102482350B (zh) * | 2009-09-08 | 2015-08-05 | 株式会社新药 | 作用于胰高血糖素受体的抗体及其应用 |
| JO3756B1 (ar) | 2010-11-23 | 2021-01-31 | Regeneron Pharma | اجسام مضادة بشرية لمستقبلات الجلوكاجون |
| US8771696B2 (en) | 2010-11-23 | 2014-07-08 | Regeneron Pharmaceuticals, Inc. | Method of reducing the severity of stress hyperglycemia with human antibodies to the glucagon receptor |
| WO2013059531A1 (en) | 2011-10-20 | 2013-04-25 | Genentech, Inc. | Anti-gcgr antibodies and uses thereof |
| US9934913B2 (en) | 2011-10-26 | 2018-04-03 | Nokia Technologies Oy | Apparatus and associated methods |
| US20140275368A1 (en) | 2013-03-14 | 2014-09-18 | Sabic Innovative Plastics Ip B.V. | Blended polymer compositions with improved mold release properties |
| SG11201508264UA (en) | 2013-05-07 | 2015-11-27 | Rinat Neuroscience Corp | Anti-glucagon receptor antibodies and methods of use thereof |
| CN104231083A (zh) * | 2013-06-09 | 2014-12-24 | 杭州鸿运华宁生物医药工程有限公司 | 抗胰高血糖素受体的抗体及其用途 |
| WO2015154795A1 (en) | 2014-04-08 | 2015-10-15 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Combination therapy for the treatment of autoimmune diseases |
| CA2950695C (en) | 2014-06-08 | 2022-12-06 | REMD Biotherapeutics, Inc | Methods for treating type 1 diabetes using glucagon receptor antagonistic antibodies |
| KR20170062466A (ko) * | 2014-09-16 | 2017-06-07 | 리제너론 파마슈티칼스 인코포레이티드 | 항-글루카곤 항체 및 그것의 사용 |
| CN107614695B (zh) | 2015-04-02 | 2022-01-25 | 瑞美德生物医药科技有限公司 | 用胰高血糖素受体拮抗性抗体治疗肥胖症和非酒精性脂肪肝病或非酒精性脂肪性肝炎的方法 |
| CA2999747A1 (en) | 2015-09-04 | 2017-03-09 | Remd Biotherapeutics, Inc. | Methods for treating heart failure using glucagon receptor antagonistic antibodies |
| WO2017062693A1 (en) | 2015-10-07 | 2017-04-13 | Remd Biotherapeutics, Inc. | Methods for treating rare genetic disorders using glucagon receptor antagonistic antibodies |
| US20190002577A1 (en) | 2016-01-04 | 2019-01-03 | Remd Biotherapeutics, Inc. | Methods Of Treating Type 2 Diabetes Mellitus Using Glucagon Receptor Antagonistic Antibodies |
| US20190248888A1 (en) | 2016-10-20 | 2019-08-15 | Regeneron Pharmaceuticals, Inc. | Methods of lowering blood glucose levels |
| MX2019008722A (es) | 2017-01-27 | 2019-10-02 | Ngm Biopharmaceuticals Inc | Proteínas de unión al receptor de glucagón y métodos para usarlas. |
| US10961315B2 (en) | 2018-07-27 | 2021-03-30 | Ngm Biopharmaceuticals, Inc. | Method of treating type I diabetes by administering a combination of a glucagon receptor antagonist and an anti-CD3 antibody |
-
2018
- 2018-01-26 MX MX2019008722A patent/MX2019008722A/es unknown
- 2018-01-26 WO PCT/US2018/015452 patent/WO2018140729A1/en unknown
- 2018-01-26 SG SG11201906682YA patent/SG11201906682YA/en unknown
- 2018-01-26 PE PE2019001477A patent/PE20191404A1/es unknown
- 2018-01-26 US US15/881,493 patent/US10995145B2/en active Active
- 2018-01-26 AU AU2018213374A patent/AU2018213374A1/en active Pending
- 2018-01-26 KR KR1020197023223A patent/KR102627311B1/ko active IP Right Grant
- 2018-01-26 JP JP2019540056A patent/JP7005638B2/ja active Active
- 2018-01-26 BR BR112019015479-5A patent/BR112019015479A2/pt unknown
- 2018-01-26 CN CN201880011175.9A patent/CN110520151B/zh active Active
- 2018-01-26 CA CA3048913A patent/CA3048913A1/en active Pending
- 2018-01-26 EP EP18744508.5A patent/EP3573651A4/en active Pending
-
2019
- 2019-06-25 IL IL267638A patent/IL267638A/en unknown
- 2019-07-09 PH PH12019501605A patent/PH12019501605A1/en unknown
- 2019-07-25 CL CL2019002081A patent/CL2019002081A1/es unknown
- 2019-08-21 CO CONC2019/0009035A patent/CO2019009035A2/es unknown
-
2021
- 2021-03-19 US US17/206,910 patent/US11732049B2/en active Active
-
2023
- 2023-06-27 US US18/342,572 patent/US20240084023A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20190113815A (ko) | 2019-10-08 |
| BR112019015479A2 (pt) | 2020-03-31 |
| US20180273629A1 (en) | 2018-09-27 |
| AU2018213374A1 (en) | 2019-07-11 |
| RU2019126781A3 (es) | 2021-10-27 |
| EP3573651A4 (en) | 2020-10-14 |
| SG11201906682YA (en) | 2019-08-27 |
| JP2020506692A (ja) | 2020-03-05 |
| EP3573651A1 (en) | 2019-12-04 |
| US20210332144A1 (en) | 2021-10-28 |
| US11732049B2 (en) | 2023-08-22 |
| MX2019008722A (es) | 2019-10-02 |
| IL267638A (en) | 2019-08-29 |
| CN110520151A (zh) | 2019-11-29 |
| PH12019501605A1 (en) | 2020-06-01 |
| CO2019009035A2 (es) | 2020-01-17 |
| RU2019126781A (ru) | 2021-03-01 |
| CL2019002081A1 (es) | 2019-12-20 |
| US20240084023A1 (en) | 2024-03-14 |
| KR102627311B1 (ko) | 2024-01-22 |
| CN110520151B (zh) | 2024-04-12 |
| CA3048913A1 (en) | 2018-08-02 |
| US10995145B2 (en) | 2021-05-04 |
| WO2018140729A1 (en) | 2018-08-02 |
| JP7005638B2 (ja) | 2022-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20191404A1 (es) | Proteinas de union al receptor de glucagon y metodos para usarlas | |
| CL2019001926A1 (es) | Anticuerpos anti-tigit y fragmentos de unión a antígeno; composición farmacéutica que los comprende; polinenucleótido que codifica dicho anticuerpo; vector que los comprende, célula hospedera; método para producir dicho anticuerpo o fragmento de unión a antígeno del mismo; y uso en el tratamiento del cáncer. (divisional de solicitud 310-2017). | |
| PE20171654A1 (es) | Composiciones y metodos usados para aumentar la respuesta inmune y en la terapia del cancer | |
| PE20191208A1 (es) | Anticuerpos anti-cd73 y usos de los mismos | |
| PE20191463A1 (es) | Anticuerpos biespecificos de union especifica pd1 y lag3 | |
| CL2021000716A1 (es) | Constructos de anticuerpo para flt3 y cd3. (divisional sol. 201800269) | |
| CO2017005650A2 (es) | Anticuerpos anti-interleucina-33 | |
| PE20181046A1 (es) | Anticuerpos anti-tigit y metodos de uso | |
| CY1120414T1 (el) | Αντισωματα που συνδεονται me οχ40 και οι χρησεις τους | |
| PE20181054A1 (es) | Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion | |
| PE20191648A1 (es) | Nuevos receptores de celulas t y terapia inmunologica que los utiliza | |
| AR096617A1 (es) | Anticuerpos anti-tweakr y sus usos | |
| PE20190976A1 (es) | Anticuerpos de union a cd3 | |
| PE20171180A1 (es) | Anticuerpos anti-pd-1 y sus metodos de uso | |
| PE20141908A1 (es) | Anticuerpos cd47 y metodos de uso los mismos | |
| AR101669A1 (es) | Constructos de anticuerpos para cdh19 y cd3 | |
| PE20180499A1 (es) | Anticuerpos de union a tau | |
| DOP2016000282A (es) | Anticuerpos humanizados contra la molécula de adhesión celular relacionada al antígeno carcinoembriónico 1 (ceacam1) | |
| PE20131209A1 (es) | Anticuerpos anti-fap | |
| AR074360A1 (es) | Anticuerpo monoclonal o fragmento de union a antigeno del mismo composicion farmaceutica que lo comprende y su uso para preparar dicha composicion | |
| ES2687282T3 (es) | Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos | |
| CL2013001279A1 (es) | Anticuerpo humano aislado o fragmento de union a antigeno del mismo que se une especificamente y neutraliza la actividad del ligando 1a de tipo tnf humano (htl1a); molecula de acido nucleico que lo codifica; vector de expresion; metodo de produccion; composicion farmaceutica que lo comprende; y su uso. | |
| CL2012000914A1 (es) | Anticuerpos monoclonales que se unen especificamente a la region c-terminal de progastrina. uso para la preparacion de un medicamento util en el tratamiento de cancer colorectal. | |
| PE20140218A1 (es) | Composicion farmaceutica | |
| EA201591153A1 (ru) | Антитела, связывающиеся с tl1a, и их применение |